Rosuvastatin-Induced reversible rhabdomyolysis

We report a case of rhabdomyolysis (RM) in a postpercutaneous transluminal coronary angioplasty patient caused by a high dose of rosuvastatin. She was admitted to the hospital with complaints of muscle weakness, myalgia, and passing red-colored urine for the last 7 days. Routine blood investigations showed serum creatinine 1.51 mg/dl, creatinine phosphokinase (CPK) 31,000 U/L, and urine myoglobin 934 ng/ml. The patient was diagnosed with rosuvastatin-induced RM. Rosuvastatin was stopped on the day of admission, and intravenous fluids were started with strict monitoring of clinical and biochemical profile. Consequently, her CPK and urine myoglobin started decreasing and her symptoms improved. The patient was discharged from the hospital on the 10th day without a statin. Rosuvastatin-induced RM is discussed as a potentially preventable life-threatening side effect.